# pleural mesothelioma stages

Malignant Mesothelioma Treatment (PDQ®) » Malignant mesothelioma treatment may include surgery, radiation therapy, and chemotherapy. Get detailed information about the diagnosis and treatment of newly diagnosed and recurrent malignant mesothelioma in this summary for clinicians. Cancer.gov

IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial. » LBA8505 Background: The vast majority of pts with PM have unresectable disease, due to co-morbidities and/or advanced stage. In unresectable PM, standard first line treatment has been C(or carboplatin)P for 20 years but it is usually only moderately efficient, mostly on epithelioid (E)PM, with a global median overall survival (mOS) around 12 months (m), an improved quality-of-life (QoL), and mild toxicity. Trial CM743 demonstrated a significant improvement in mOS for nivolumab/ipilimumab (NI) over CP (18.1 versus 14.1 m), particularly for non-EPM, but 30% NI pts experienced > grade 3 toxicity. Thus, alternative therapies to improve mOS and tolerability are needed. Methods: Canadian Cancer Trials Group (CCTG) IND 227 is an academic, open-label, randomized P3 study of the CCTG, National Cancer Institute of Naples (NCIN) and Intergroupe Francophone de Cancérologie Thoracique (IFCT). The study was supported by grants to CCTG (Canadian Cancer Society -707213); Merck & Co. Inc provided pembrolizumab (pembro) and a Ascopubs.org

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses » Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses - NCT02467270 Cancer.gov

Diagnosis and management of patients with malignant peritoneal mesothelioma » Malignant peritoneal mesothelioma (MPM) is a rare neoplastic condition that arises, usually diffusely, from the serosal membranes of the abdominal cavity. MPM represents about 7% to 10% of all mesothelioma diagnoses and this translates into approximately… Ncbi.nlm.nih.gov

Pleural Thickening & Asbestos: Causes, Symptoms & Treatment » Pleural thickening occurs when scar tissue thickens the thin membrane covering the lungs. Learn more about what pleural thickening is. Asbestos.com

Pleural Thickening | Symptoms, Causes and Treatment » Pleural thickening is treatable scarring of the lining around the lungs. It can be caused by asbestos exposure and may be a sign of mesothelioma. Mesothelioma.com